NewAmsterdam Pharma Outlines 2025 Strategy With Obicetrapib Focus; Expects EMA Filing In H2 2025, Unveils $835M Year-End Cash. Highlights: BROADWAY 33% LDL-C Reduction, TANDEM 49% Reduction, BROOKLYN 36% Reduction; PREVAIL Trial Ongoing. VINCENT &...

BenzingaJan 10 21:13

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

GlobeNewswireJan 10 21:00

Express News | NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BreakingsJan 10 04:38

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireJan 10 04:38

Merck Downgraded by Truist to Hold Over Growth Concerns

Seeking AlphaJan 8 23:19

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and NewAmsterdam Pharma Company (NAMS)

TipRanksDec 30, 2024 19:40 · Ratings